December 12, 2023 02:19 PM ESTUpdated December 15, 12:14 PM
R&D

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Ayisha Sharma

News Reporter

Dizal said its pe­riph­er­al T-cell lym­phoma drug can­di­date showed pos­i­tive ef­fi­ca­cy and safe­ty in a Phase II reg­is­tra­tional tri­al, paving the way for a US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times